D. Hamish Wright - Concepedia

Author

D. Hamish Wright

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

D Hamish Wright, D. Hamish Wright, D. Wright, D.Hamish Wright, DH Wright, Duncan Hamish Wright

Publications

415

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)McGill University Merck Canada Inc. (Canada)

About

D. Hamish Wright is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	152
2	Pharmacology	3	3	152
3	Immunology	2	2	133
4	Diabetes	1	1	19
5	Endocrinology	1	1	64

D. Hamish Wright

Publications

308

Citations

H-Index

Page 1

	Year	Citations
Characterization of the recombinant human prostanoid DP receptor and identification of L‐644,698, a novel selective DP agonist D. Hamish Wright, Kathleen M. Metters, Mark Abramovitz, British Journal of Pharmacology	1998	76
Expression of prostaglandin D synthase and the prostaglandin D2 receptors DP and CRTH2 in human nasal mucosa F. Nantel, Carolyn Fong, Sonia Lamontagne, Prostaglandins & Other Lipid Mediators Signal TransductionProstaglandin D SynthaseAutoimmune DiseaseMedicineImmunology	2004	69
A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor D. Hamish Wright, F. Nantel, Kathleen M. Metters, European Journal of Pharmacology NeuropeptidesGastrointestinal Peptide HormoneMolecular PhysiologySignal TransductionMedicine	1999	64
The human prostanoid DP receptor stimulates mucin secretion in LS174T cells D. Hamish Wright, Anthony W. Ford‐Hutchinson, Kris Chadee, British Journal of Pharmacology	2000	48
Multiple Doses of Sitagliptin, a Selective DPP‐4 Inhibitor, Do Not Meaningfully Alter Pharmacokinetics and Pharmacodynamics of Warfarin D. Hamish Wright, Gary Herman, Andrea Maes, The Journal of Clinical Pharmacology ThrombosisDiabetes ManagementWarfarin 30Cardiovascular DiseaseMultiple Doses	2009	19
Pharmacokinetic–pharmacodynamic studies of the 11β‐hydroxysteroid dehydrogenase type 1 inhibitor <scp>MK</scp>‐0916 in healthy subjects D. Hamish Wright, Julie A. Stone, Tami M. Crumley, British Journal of Clinical Pharmacology	2013	18
Liver-to-Plasma Vaniprevir (MK-7009) Concentration Ratios in HCV-Infected Patients D. Hamish Wright, Luzelena Caro, Michael Cerra, Antiviral Therapy	2014	14

Page 1